Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 52, Issue 2, Pages 330-340Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2011.07.029
Keywords
cGMP; Cardiovascular disease; Soluble guanylyl cyclase; Natriuretic peptide receptor; PKG; Phosphodiesterases
Categories
Funding
- Fondation Jean Leducq (Transatlantic Network of Excellence in Cardiovascular Biology)
- European Commission
- The Politique Scientifique Federale [IUAP P6/30]
- Action de Recherche Concertee (from the Communaute Francaise de Belgique)
- Fonds National de la Recherche Scientifique (FNRS, Belgium)
Ask authors/readers for more resources
Cyclic guanosine 3'5'monophosphate (cGMP) is the common downstream second messenger of natriuretic peptides and nitric oxide. In cardiac myocytes, the physiological effects of cGMP are exerted through the activation of protein kinase G (PKG) signaling, and the activation and/or inhibition of phosphodiesterases (PDEs), providing an integration point between cAMP and cGMP signals. Specificity of cGMP signals is achieved through compartmentalization of cGMP synthesis by guanylate cyclases, and cGMP hydrolysis by PDEs. Increasing evidence suggests that cGMP-dependent signaling pathways play an important role in inhibiting cardiac remodeling, through the inhibition Ca2+ handling upstream of pathological Ca2+-dependent signaling pathways. Thus, enhancing cardiac myocyte cGMP signaling represents a promising therapeutic target for treatment of cardiovascular disease. This article is part of a Special Issue entitled Local Signaling in Myocytes. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available